 |
29 Diseases |  |
85 Trials |
|
85 Trials |  |
3645 News |  |
| «12...34353637383940414243444546 |
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial primary completion date: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=126, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2016 --> Sep 2017
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2015
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2016 --> Sep 2017 Suspended --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial, Minimal residual disease: Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease (clinicaltrials.gov) - May 29, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Blincyto (blinatumomab) / Astellas, Amgen
Clinical: Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 9, 2015
P1/2, N=39, Not yet recruiting, Sponsor: Amgen
- |||||||||| New P3 trial: Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 20, 2015
P3, N=320, Not yet recruiting, Sponsor: Amgen
- Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 9, 2015
P3, N=598, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Feb 19, 2015
P3, N=400, Recruiting, Sponsor: Amgen
Recruiting --> Suspended Trial primary completion date: May 2016 --> Aug 2016
- Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 28, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> Aug 2016 Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Alcantara: Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 26, 2015
P2, N=45, Active, not recruiting, Sponsor: Amgen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jan 22, 2015
P2, N=225, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Oct 2013
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: Study of the BiTE (clinicaltrials.gov) - Jan 7, 2015
P2, N=36, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Trial primary completion date: Jun 2014 --> Oct 2013 N=25 --> 36
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion, Trial initiation date, Trial primary completion date, Minimal residual disease: Phase II Study of the BiTE (clinicaltrials.gov) - Jan 7, 2015
P2, N=21, Completed, Sponsor: Amgen Research (Munich) GmbH
N=25 --> 36 Active, not recruiting --> Completed | Initiation date: Oct 2007 --> Jan 2008 | Trial primary completion date: Dec 2009 --> Sep 2009
- | Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 19, 2014
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Initiation date: Oct 2007 --> Jan 2008 | Trial primary completion date: Dec 2009 --> Sep 2009 Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014
- Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014 Initiation date: Aug 2014 --> Jan 2015
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change, Trial primary completion date: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 3, 2014
P2, N=225, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Initiation date: Aug 2014 --> Jan 2015 N=180 --> 225 | Trial primary completion date: Dec 2013 --> Jun 2014
- Blincyto (blinatumomab) / Astellas, Amgen
New trial: RIALTO: Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=0, Available, Sponsor: Amgen
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 8, 2014
P2, N=84, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
N=180 --> 225 | Trial primary completion date: Dec 2013 --> Jun 2014 Recruiting --> Active, not recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 2, 2014
P2, N=25, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2014
P3, N=438, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Minimal residual disease: Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jan 21, 2014
P2, N=130, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Alcantara: Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 15, 2014
P2, N=41, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 5, 2014
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: TOWER: Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Dec 15, 2013
P3, N=400, Recruiting, Sponsor: Amgen
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 4, 2013
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Alcantara: Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 2, 2013
P2, N=41, Recruiting, Sponsor: Amgen
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 19, 2013
P2, N=180, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment change: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 26, 2013
P1/2, N=106, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=66 --> 106
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jan 3, 2013
P2, N=180, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
N=66 --> 106 N=150 --> 180
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Dec 3, 2012
P2, N=25, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
- || Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL (clinicaltrials.gov) - Nov 19, 2012
P1, N=76, Completed, Sponsor: Amgen Research (Munich) GmbH
N=150 --> 180 N=60 --> 76
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed, Minimal residual disease: Phase II Study of the BiTE (clinicaltrials.gov) - Nov 19, 2012
P2, N=21, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
N=60 --> 76 Completed --> Active, not recruiting
- ||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion: Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL (clinicaltrials.gov) - Nov 19, 2012
P1, N=76, Completed, Sponsor: Amgen Research (Munich) GmbH
Completed --> Active, not recruiting Active, not recruiting --> Completed
- |||| Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 2, 2012
P2, N=84, Recruiting, Sponsor: Amgen Research (Munich) GmbH
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: Study of the BiTE (clinicaltrials.gov) - Dec 14, 2011
P2, N=25, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 14, 2011
P2, N=84, Recruiting, Sponsor: Amgen Research (Munich) GmbH
- ||||| Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Nov 3, 2011
P2, N=180, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
- |||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment open: NCI-2011-01123: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 28, 2011
P1/2, N=106, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting